Restricted accessResearch articleFirst published online 2017-09
Editorial Comment on: Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term Outcomes by Metcalfe et al.
ColinP, RouprêtM, GhoneimTP, TraxerO, ZerbibM, XylinasE. Conservative management of upper tract urothelial carcinoma in France: A 2004–2011 national practice report. Eur Urol, 2013; 63:405–406.
4.
AudenetF, TraxerO, BensalahK, RouprêtM. Upper urinary tract instillations in the treatment of urothelial carcinomas: A review of technical constraints and outcomes. World J Urol, 2013; 31:45–52.
5.
AboumarzoukOM, SomaniBK, NabiG, KataSG, TownellN, KataSG. Mitomycin C instillation following ureterorenoscopic laser ablation of upper urinary tract carcinoma. Urol Ann, 2013; 5:184–189.
6.
MetcalfeM, WagenheimG, XiaoL, et al.Induction and maintenance adjuvant mitomycin C topical therapy for upper tract urothelial carcinoma: Tolerability and intermediate term outcomes. J Endourol, 2017. [Epub ahead of print]; DOI: 10.1089/end.2016.0871.
7.
BosschieterJ, NieuwenhuijzenJA, van GinkelT, VisAN, WitteB, NewlingD, BeckersGMA, MoorselaarRJAV. Value of an immediate intravesical instillation of mitomycin C in patients with non-muscle-invasive bladder cancer: A prospective multicentre randomised study in 2243 patients. Eur Urol, 2017. [Epub ahead of print]; DOI: 10.1016/j.eururo.2017.06.038.
8.
A Phase 3 multicenter Trial Evaluating the Efficacy and Safety of MitoGel™ on ablation of upper urinary tract urothelial carcinoma. Available at: https://clinicaltrials.gov/ct2/show/NCT02793128 (accessed on July2017).
